Kinetics Medical Adv C (KRXCX)

25.05 +0.36  +1.46% Jul 14 USD
View Full Chart
Total Returns Chart

Key Stats

Net Asset Value 25.05
Turnover Ratio 6.00%
1 Year Fund Level Flows 1.202M

Performance & Returns

  Total Return Cat. Total Return (NAV) % Rank in Cat. (NAV)
1M 6.55% 7.54% 67
3M 5.92% 15.22% 98
6M 0.72% 6.48% 84
YTD 2.08% 7.69% 82
1Y 15.92% 20.34% 66
3Y 5.99% 11.30% 86
5Y 1.72% 6.05% 89
10Y 10.11% 15.92% 98
15Y 8.33% 11.17% --
20Y 4.92% 9.02% --
As of July 14, 2020. Returns for periods of 1 year and above are annualized.

Asset Allocation

Type % Net % Long % Short
Cash 0.44% 0.44% 0.00%
Stock 99.55% 99.55% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.01% 0.01% 0.00%
As of March 31, 2020

Region Exposure

Americas 73.67%
North America 73.67%
Latin America 0.00%
Greater Europe 26.33%
United Kingdom 11.80%
Europe Developed 14.53%
Europe Emerging 0.00%
Africa/Middle East 0.00%
Greater Asia 0.00%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.00%
Market Classification
% Developed Markets 100.00%
% Emerging Markets 0.00%
As of March 31, 2020. Region breakdown data is calculated by using the long position holdings of the portfolio.

Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 100.0%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of March 31, 2020

Stock Market Capitalization

Giant 74.88%
Large 13.86%
Medium 5.38%
Small 4.95%
Micro 0.93%
As of March 31, 2020

Stock Style Exposure

Large Cap Value 47.67%
Large Cap Blend 32.93%
Large Cap Growth 8.13%
Mid Cap Value 0.00%
Mid Cap Blend 0.00%
Mid Cap Growth 5.38%
Small Cap Value 0.13%
Small Cap Blend 3.16%
Small Cap Growth 2.59%
As of March 31, 2020
View More Holdings

Top 10 Holdings

Symbol Name % Weight Price % Chg
BMY Bristol-Myers Squibb Company 8.98% 59.26 +2.37%
BIIB Biogen Inc 8.13% 283.00 +0.62%
LLY Eli Lilly and Co 8.08% 165.06 +0.72%
NVS Novartis AG ADR 7.91% 87.86 +0.45%
MRK Merck & Co Inc 7.91% 79.44 +1.52%
JNJ Johnson & Johnson 7.19% 148.00 +0.05%
PFE Pfizer Inc 6.71% 35.65 +1.19%
AZN AstraZeneca PLC ADR 6.12% 59.20 +9.67%
GILD Gilead Sciences Inc 5.64% 76.58 -0.79%
GSK GlaxoSmithKline PLC ADR 5.63% 42.10 +3.44%
As of March 31, 2020
Advertisement

Basic Info

Investment Strategy
The investment seeks long-term growth of capital. The fund is a non-diversified fund that invests all of its investable assets in the Medical Portfolio, a series of Kinetics Portfolios Trust. The Portfolio invests at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants, and other equity securities having the characteristics of common stocks of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries, with an emphasis toward companies engaged in cancer research and drug development. It is non-diversified.
General
Security Type Mutual Fund
Oldest Share Symbol MEDRX
Equity Style Large Cap/Blend
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Prospectus Objective Specialty - Health
Fund Owner Firm Name Kinetics
Benchmark Index
S&P 500 TR USD 100.0%
Reports
One Page Report Download

Manager Info

Name Tenure
Bruce Abel 20.77 yrs

Share Classes

Symbol Share Class
KRXAX A
MEDRX No Load

Net Fund Flows

1M -67529.15
3M 2.998M
6M 2.367M
YTD 2.367M
1Y 1.202M
3Y -4.190M
5Y -10.91M
10Y -31.70M
As of June 30, 2020

Risk Info

Beta (5Y) 0.7314
Historical Sharpe Ratio (10Y) 0.6893
Historical Sortino (All) 0.6532
Daily Value at Risk (VaR) 1% (All) 3.05%
Monthly Value at Risk (VaR) 1% (All) 14.75%

Fundamentals

Dividend Yield TTM (7-14-20) 0.36%
30-Day SEC Yield --
7-Day SEC Yield (12-30-10) 0.02%
Weighted Average PE Ratio 18.57
Weighted Average Price to Sales Ratio 3.906
Weighted Average Price to Book Ratio 4.071
Weighted Median ROE 30.26%
Weighted Median ROA 9.35%
Forecasted Dividend Yield 2.97%
Forecasted PE Ratio 12.68
Forecasted Price to Sales Ratio 3.200
Forecasted Price to Book Ratio 4.089
Number of Holdings 30
As of March 31, 2020

Growth Estimates

Forecasted 5 Yr Earnings Growth 17.50%
Forecasted Book Value Growth 11.89%
Forecasted Cash Flow Growth -9.28%
Forecasted Earnings Growth 71.28%
Forecasted Revenue Growth 7.29%
As of March 31, 2020

Comparables

Edit

Attributes

Purchase Details
Open to New Investors Yes
Open to Existing Investors Yes
Minimum Initial Investment 2500.00 USD
Minimum Subsequent Investment 0.00 USD
Fees
Actual 12B-1 Fee 1.00%
Actual Management Fee 1.25%
Administration Fee --
Performance Fee --
Switching Fee --
Transaction Fee --
Maximum Front Load --
Maximum Deferred Load 1.00%
Maximum Redemption Fee 2.00%
Key Dates
Inception Date 2/16/2007
Termination Date
Last Annual Report Date 12/31/2019
Last Prospectus Date 4/29/2020
Attributes
Exchange Traded Share No
Exchange Traded Note No
Enhanced Index Fund No
Fixed Distribution Fund No
High-Net Worth Individual Fund No
Index Fund No
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.